Name | Number of supported studies | Average coverage | |
---|---|---|---|
smooth muscle cell | 8 studies | 23% ± 7% | |
cardiac muscle cell | 5 studies | 41% ± 8% | |
muscle cell | 3 studies | 40% ± 27% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
heart | 3 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 85% | 5809.14 | 209 / 245 | 97% | 11.28 | 487 / 502 |
uterus | 95% | 10564.44 | 161 / 170 | 49% | 10.07 | 224 / 459 |
esophagus | 77% | 11696.68 | 1118 / 1445 | 65% | 4.64 | 119 / 183 |
bladder | 86% | 9148.95 | 18 / 21 | 52% | 3.30 | 260 / 504 |
intestine | 73% | 8491.69 | 710 / 966 | 48% | 2.17 | 255 / 527 |
breast | 44% | 1045.23 | 200 / 459 | 57% | 2.38 | 634 / 1118 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.79 | 1 / 1 |
blood vessel | 99% | 10555.56 | 1327 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 11083.60 | 791 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 10438.15 | 832 / 861 | 0% | 0 | 0 / 0 |
stomach | 42% | 3109.33 | 150 / 359 | 54% | 5.27 | 155 / 286 |
kidney | 2% | 43.22 | 2 / 89 | 85% | 5.51 | 767 / 901 |
brain | 0% | 5.30 | 6 / 2642 | 73% | 2.47 | 515 / 705 |
pancreas | 0% | 0 | 0 / 328 | 72% | 3.08 | 129 / 178 |
lung | 32% | 683.88 | 187 / 578 | 35% | 2.03 | 409 / 1155 |
ovary | 13% | 580.03 | 23 / 180 | 45% | 1.44 | 192 / 430 |
adrenal gland | 1% | 12.79 | 2 / 258 | 36% | 1.25 | 82 / 230 |
adipose | 28% | 767.72 | 338 / 1204 | 0% | 0 | 0 / 0 |
thymus | 4% | 94.48 | 25 / 653 | 24% | 0.45 | 144 / 605 |
skin | 7% | 144.17 | 128 / 1809 | 11% | 0.43 | 50 / 472 |
eye | 0% | 0 | 0 / 0 | 10% | 0.18 | 8 / 80 |
tonsil | 0% | 0 | 0 / 0 | 9% | 0.37 | 4 / 45 |
liver | 0% | 0 | 0 / 226 | 7% | 0.21 | 28 / 406 |
peripheral blood | 0% | 8.13 | 4 / 929 | 0% | 0 | 0 / 0 |
spleen | 0% | 9.29 | 1 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0055074 | Biological process | calcium ion homeostasis |
GO_0055024 | Biological process | regulation of cardiac muscle tissue development |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0060316 | Biological process | positive regulation of ryanodine-sensitive calcium-release channel activity |
GO_0060402 | Biological process | calcium ion transport into cytosol |
GO_0060314 | Biological process | regulation of ryanodine-sensitive calcium-release channel activity |
GO_0005886 | Cellular component | plasma membrane |
GO_0030018 | Cellular component | Z disc |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0014701 | Cellular component | junctional sarcoplasmic reticulum membrane |
GO_0030314 | Cellular component | junctional membrane complex |
GO_0016529 | Cellular component | sarcoplasmic reticulum |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0005547 | Molecular function | phosphatidylinositol-3,4,5-trisphosphate binding |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0070273 | Molecular function | phosphatidylinositol-4-phosphate binding |
GO_0005546 | Molecular function | phosphatidylinositol-4,5-bisphosphate binding |
GO_0001786 | Molecular function | phosphatidylserine binding |
GO_0032266 | Molecular function | phosphatidylinositol-3-phosphate binding |
GO_0080025 | Molecular function | phosphatidylinositol-3,5-bisphosphate binding |
GO_0070300 | Molecular function | phosphatidic acid binding |
GO_0005515 | Molecular function | protein binding |
GO_0010314 | Molecular function | phosphatidylinositol-5-phosphate binding |
Gene name | JPH2 |
Protein name | JPH2 protein Junctophilin-2 (JP-2) (Junctophilin type 2) [Cleaved into: Junctophilin-2 N-terminal fragment (JP2NT)] |
Synonyms | JP2 |
Description | FUNCTION: [Junctophilin-2]: Membrane-binding protein that provides a structural bridge between the plasma membrane and the sarcoplasmic reticulum and is required for normal excitation-contraction coupling in cardiomyocytes . Provides a structural foundation for functional cross-talk between the cell surface and intracellular Ca(2+) release channels by maintaining the 12-15 nm gap between the sarcolemma and the sarcoplasmic reticulum membranes in the cardiac dyads (By similarity). Necessary for proper intracellular Ca(2+) signaling in cardiac myocytes via its involvement in ryanodine receptor-mediated calcium ion release (By similarity). Contributes to the construction of skeletal muscle triad junctions (By similarity). .; FUNCTION: [Junctophilin-2 N-terminal fragment]: Transcription repressor required to safeguard against the deleterious effects of cardiac stress. Generated following cleavage of the Junctophilin-2 chain by calpain in response to cardiac stress in cardiomyocytes. Following cleavage and release from the membrane, translocates to the nucleus, binds DNA and represses expression of genes implicated in cell growth and differentiation, hypertrophy, inflammation and fibrosis. Modifies the transcription profile and thereby attenuates pathological remodeling in response to cardiac stress. Probably acts by competing with MEF2 transcription factors and TATA-binding proteins. . |
Accessions | ENST00000342272.3 [Q9BR39-2] Q9BR39 ENST00000372980.4 [Q9BR39-1] Q86VZ3 |